Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

PDF  |  How to cite

Oncotarget. 2024; 15:354-354. https://doi.org/10.18632/oncotarget.28580

Metrics: PDF 119 views  |   ?  

Mohammad Krayem1, Ahmad Najem1, Fabrice Journe1,2, Renato Morandini1, François Sales1, Ahmad Awada3 and Ghanem E. Ghanem1

1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
2Service d’Anatomie Humaine et d’Oncologie Expérimentale, Université de Mons, Mons, Belgium
3Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Published: June 03, 2024

Copyright: © 2024 Krayem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: Multiple internal duplications of western blot images illustrating the data of different experiments have been discovered throughout Figure 3C. In addition, Figure 3C also contains blots images from Figure 2A in an earlier published paper [1]. Therefore, with the agreement of all authors, the Scientific Integrity office at Oncotarget has decided to retract this paper.


1. Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Eur J Cancer. 2016; 55:98–110. https://doi.org/10.1016/j.ejca.2015.12.002. [PubMed].

Original article: Oncotarget. 2018; 9:31888–31903. DOI: https://doi.org/10.18632/oncotarget.25879

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28580